Bone Sialoprotein, Matrix Metalloproteinase 2, and v 3 Integrin in Osteotropic Cancer Cell Invasion
Open Access
- 15 June 2004
- journal article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 96 (12) , 956-965
- https://doi.org/10.1093/jnci/djh169
Abstract
Background: Bone sialoprotein (BSP) interacts separately with both matrix metalloproteinase 2 (MMP-2) and integrin αvβ3 and is overexpressed in many metastatic tumors. Its role in tumor biology, however, remains unclear. We investigated whether BSP enhances cancer cell invasiveness by forming a trimolecular complex with MMP-2 and cell-surface integrin αvβ3. Methods: Invasiveness of breast, prostate, lung, and thyroid tumor cell lines was measured with a modified Boyden chamber assay. Binding and co-localization of BSP, MMP-2, and integrin αvβ3 were investigated with immunoprecipitation and in situ hybridization. All statistical tests were two-sided. Results: Treatment with BSP increased invasiveness of many breast, prostate, lung, and thyroid cancer cells through Matrigel in a dose-dependent manner. BSP at 50 nM increased the invasiveness of SW-579 thyroid cancer cells (95.2 units, 95% confidence interval [CI] = 90.4 to 100 units) by approximately 10-fold compared with that of untreated control SW-579 cells (9.1 units, 95% CI = 5.7 to 12.5 units) (P<.001). Addition of an inactive mutated BSP, in which BSP's integrin-binding RGD tripeptide was altered, or addition of integrin αvβ3-blocking antibodies resulted in invasiveness equivalent to that of untreated cells. Inhibiting cellular MMP-2 activity with chemical inhibitors or a specific antibody also blocked BSP-enhanced invasiveness. Osteopontin and dentin matrix protein 1, proteins related to BSP that also bind integrin αvβ3 and form complexes with other MMPs (but not MMP-2), did not enhance invasiveness. Immunoprecipitation showed that a complex containing BSP, integrin αvβ3, and MMP-2 formed in vitro. Addition of BSP increased the amount of MMP-2 bound by cells in an integrin-dependent fashion. Co-expression of BSP, integrin αvβ3, and MMP-2 in papillary thyroid carcinoma cells was shown by in situ hybridization. Conclusion: Cancer cells appear to become more invasive when BSP forms a cell-surface trimolecular complex by linking MMP-2 to integrin αvβ3.Keywords
This publication has 37 references indexed in Scilit:
- Osteopontin: a bridge between bone and the immune systemJournal of Clinical Investigation, 2003
- Osteopontin Traffic in Hypoxic Renal Epithelial CellsNephron Experimental Nephrology, 2003
- Three SIBLINGs (SmallIntegrin-Binding LIgand, -linked Glycoproteins) Enhance Factor H's Cofactor Activity Enabling MCP-like Cellular Evasion of Complement-mediated AttackJournal of Biological Chemistry, 2002
- Flexible Structures of SIBLING Proteins, Bone Sialoprotein, and OsteopontinBiochemical and Biophysical Research Communications, 2001
- Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated AttackJournal of Biological Chemistry, 2000
- Co-expression of osteopontin and CD44v9 in gastric cancerInternational Journal of Cancer, 1998
- Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1)Science, 1996
- Regulated Expression of Osteopontin in Human TrophoblastsAnnals of the New York Academy of Sciences, 1995
- Osteopontin in human milk from mothers of premature infantsActa Paediatrica, 1993
- Expression of bone sialoprotein (BSP) in developing human tissuesCalcified Tissue International, 1991